Velan Capital Investment Management LP
13F Reported Value
ⓘ$159.6M
Holdings
49
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Velan Capital Investment Management LP disclosed 49 positions worth $159.6M in its Form 13F-HR for Q1 2026, led by $PRAX (Praxis Precision Medicines, Inc.) at 20.3% of the equity portfolio, followed by $TARA and $STRO. During the quarter the fund opened 11 new positions and exited 8 — including a new stake in $AVR. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Velan Capital Investment Management LP’s Form 13F-HR filing with the SEC under CIK 1848809.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- $32.5M100,781 sh
- —
Quality
$14.8M2,834,652 sh - 30.1#2,372
Quality
$12.8M512,160 sh - —
Quality
$10.3M446,255 sh - —
Quality
$10.0M492,893 sh - —
Quality
$9.3M583,333 sh - —
Quality
$8.6M77,000 sh - 30.6
Quality
$7.0M8,753,290 sh - —
Quality
$6.7M740,000 sh - 34.3
Quality
$4.7M1,720,000 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Praxis Precision Medicines, Inc.$PRAX | — | $32.5M | 100,781 |
 Protara Therapeutics, Inc.$TARA | — | $14.8M | 2,834,652 |
 SUTRO BIOPHARMA, INC.$STRO | 30.1#2,372 | $12.8M | 512,160 |
 Evommune, Inc.$EVMN | — | $10.3M | 446,255 |
 MapLight Therapeutics, Inc.$MPLT | — | $10.0M | 492,893 |
 TENAX THERAPEUTICS, INC.$TENX | — | $9.3M | 583,333 |
 Abivax S.A.$ABVX | — | $8.6M | 77,000 |
 HERON THERAPEUTICS, INC. /DE/$HRTX | 30.6 | $7.0M | 8,753,290 |
 Immix Biopharma, Inc.$IMMX | — | $6.7M | 740,000 |
 Esperion Therapeutics, Inc.$ESPR | 34.3 | $4.7M | 1,720,000 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Velan Capital Investment Management LP's 49 positions.
Showing top 10 of 49 holdings.
Sector Allocation
Healthcare
$159.6M
Full Holdings — Velan Capital Investment Management LP (Q1 2026)
All 49 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $PRAX | Praxis Precision Medicines, Inc. | $32.5M | 20.3% | +0% | — |
| 2 | $TARA | Protara Therapeutics, Inc. | $14.8M | 9.3% | +0% | — |
| 3 | $STRO | SUTRO BIOPHARMA, INC. | $12.8M | 8.0% | +64% | 30.1 |
| 4 | $EVMN | Evommune, Inc. | $10.3M | 6.4% | -12% | — |
| 5 | $MPLT | MapLight Therapeutics, Inc. | $10.0M | 6.3% | -6% | — |
| 6 | $TENX | TENAX THERAPEUTICS, INC. | $9.3M | 5.8% | +600% | — |
| 7 | $ABVX | Abivax S.A. | $8.6M | 5.4% | +15% | — |
| 8 | $HRTX | HERON THERAPEUTICS, INC. /DE/ | $7.0M | 4.4% | +0% | 30.6 |
| 9 | $IMMX | Immix Biopharma, Inc. | $6.7M | 4.2% | +2014% | — |
| 10 | $ESPR | Esperion Therapeutics, Inc. | $4.7M | 3.0% | +42% | 34.3 |
| 11 |  $EDSA | Edesa Biotech, Inc. | $4.3M | 2.7% | +20% | — |
| 12 |  $AVR | Anteris Technologies Global Corp. | $3.9M | 2.4% | NEW | — |
| 13 |  $NSPR | InspireMD, Inc. | $3.4M | 2.1% | -2% | — |
| 14 |  $XNCR | Xencor Inc | $3.0M | 1.9% | NEW | 13.1 |
| 15 |  $AVTX | Avalo Therapeutics, Inc. | $2.8M | 1.7% | -30% | 4.6 |
| 16 |  $EPRX | EUPRAXIA PHARMACEUTICALS INC. | $2.5M | 1.6% | +0% | — |
| 17 |  $CTMX | CytomX Therapeutics, Inc. | $2.5M | 1.6% | +575% | 19.1 |
| 18 |  $VRCA | Verrica Pharmaceuticals Inc. | $2.5M | 1.6% | +0% | 26.1 |
| 19 |  $JSPR | Jasper Therapeutics, Inc. | $2.3M | 1.5% | +0% | — |
| 20 |  $RZLT | Rezolute, Inc. | $2.3M | 1.4% | +0% | — |
| 21 |  $LYEL | Lyell Immunopharma, Inc. | $2.0M | 1.3% | NEW | 3.6 |
| 22 |  $PROF | Profound Medical Corp. | $1.9M | 1.2% | +0% | — |
| 23 |  $VRDN | Viridian Therapeutics, Inc.\DE | $1.8M | 1.1% | +5% | 30.5 |
| 24 |  $RCKT | ROCKET PHARMACEUTICALS, INC. | $1.1M | 0.7% | NEW | — |
| 25 |  $KZIA | KAZIA THERAPEUTICS LTD | $1.0M | 0.6% | -55% | — |
| 26 |  $NSRX | Nasus Pharma Ltd | $797,846 | 0.5% | NEW | — |
| 27 |  $QNRX | Quoin Pharmaceuticals, Ltd. | $560,003 | 0.3% | NEW | — |
| 28 |  $ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $407,550 | 0.3% | +0% | 74.4 |
| 29 |  $PTGX | Protagonist Therapeutics, Inc | $389,980 | 0.2% | +0% | 24.8 |
| 30 |  $OVID | Ovid Therapeutics Inc. | $355,200 | 0.2% | +0% | 13.1 |
| 31 |  $MLYS | Mineralys Therapeutics, Inc. | $297,990 | 0.2% | -93% | — |
| 32 |  $CNTX | Context Therapeutics Inc. | $262,000 | 0.2% | +0% | — |
| 33 |  $NRIX | Nurix Therapeutics, Inc. | $248,000 | 0.2% | +0% | 13.2 |
| 34 |  $CRBP | Corbus Pharmaceuticals Holdings, Inc. | $244,140 | 0.1% | +100% | — |
| 35 |  $SNDX | Syndax Pharmaceuticals Inc | $233,600 | 0.1% | -92% | 30 |
| 36 |  $DTIL | PRECISION BIOSCIENCES INC | $220,000 | 0.1% | +100% | 3.9 |
| 37 |  $IMNM | Immunome Inc. | $218,700 | 0.1% | +0% | 5.8 |
| 38 |  $DSGN | Design Therapeutics, Inc. | $212,800 | 0.1% | +0% | — |
| 39 |  $ARTV | Artiva Biotherapeutics, Inc. | $161,000 | 0.1% | NEW | — |
| 40 |  $NMRA | Neumora Therapeutics, Inc. | $156,000 | 0.1% | NEW | — |
| 41 |  $REPL | Replimune Group, Inc. | $153,000 | 0.1% | +33% | — |
| 42 |  $LRMR | Larimar Therapeutics, Inc. | $148,500 | 0.1% | +0% | — |
| 43 |  $XLO | Xilio Therapeutics, Inc. | $120,137 | 0.1% | -92% | 26.9 |
| 44 |  $KLRS | Kalaris Therapeutics, Inc. | $103,860 | 0.1% | NEW | — |
| 45 |  $PMVP | PMV Pharmaceuticals, Inc. | $90,520 | 0.1% | +109% | — |
| 46 |  $MGNX | MACROGENICS INC | $86,700 | 0.1% | NEW | 31.7 |
| 47 |  $KPTI | Karyopharm Therapeutics Inc. | $83,550 | 0.1% | NEW | 20.4 |
| 48 |  $PRQR | ProQR Therapeutics N.V. | $72,900 | 0.1% | +0% | — |
| 49 |  $GOSS | Gossamer Bio, Inc. | $22,995 | 0.0% | +0% | 27.1 |
New Positions (11)
$AVR Anteris Technologies Global Corp.$3.9M$XNCR Xencor Inc$3.0M$LYEL Lyell Immunopharma, Inc.$2.0M$RCKT ROCKET PHARMACEUTICALS, INC.$1.1M$NSRX Nasus Pharma Ltd$797,846$QNRX Quoin Pharmaceuticals, Ltd.$560,003$ARTV Artiva Biotherapeutics, Inc.$161,000$NMRA Neumora Therapeutics, Inc.$156,000$KLRS Kalaris Therapeutics, Inc.$103,860$MGNX MACROGENICS INC$86,700$KPTI Karyopharm Therapeutics Inc.$83,550
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Velan Capital Investment Management LP including:
Track Velan Capital Investment Management LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Velan Capital Investment Management LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Velan Capital Investment Management LP
13F Pro is an AI hedge fund tracker and stock research platform. For Velan Capital Investment Management LP (SEC CIK: 1848809), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Velan Capital Investment Management LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.